ers. We calculated population-based rates of SPECT-MPI as well as rates for alternative testing modalities (stress echocardiography, computed tomography coronary angiography, and positron emission tomography-MPI) and downstream cardiac catheterization less than 90 days after index testing. We identified a priori the 6-month shortage during March through August 2010 due to shutdowns at the Petten High Flux and Chalk River Laboratories reactors, the 2 major producers of 99 Mo for the United States. We used descriptive statistics to document temporal trends. Multivariable logistic regression was used to estimate the odds of cardiac catheterization less than 90 days after SPECT-MPI depending on radiotracer use after adjusting for age, sex, and race. This study was approved by the University of Michigan Institutional Review Board. Informed consent was waived for this retrospective study.
Results | During the shortage, 99m
Tc use fell nearly one-fourth from 64% of SPECT-MPI in February 2010 just prior to the shortage to a low point of 49% in May 2010 (Figure, A) . Despite a partial rebound after the shortage, 99m Tc use continued to decline, accounting for 52% of SPECT-MPI in September 2012. We observed steadily declining use of SPECT-MPI throughout the study period with stable rates of stress echocardiography, computed tomography coronary angiography, and positron emission tomography-MPI during the shortage (Figure, B) . The adjusted odds of undergoing cardiac catheterization less than 90 days after SPECT-MPI was higher during the shortage (odds ratio = 1.09; 95% CI, 1.07-1.10; P < .001). Given the frequency of SPECT-MPI, 5715 excess cardiac catheterizations may have occurred among Medicare beneficiaries.
Discussion | Recent shortages of 99m
Tc were associated with major shifts in its use during cardiac stress testing and an increase in downstream cardiac catheterization. Although changing referral patterns could contribute, we did not observe meaningful deviations from long-term trends in use of SPECT-MPI or alternative imaging tests during the shortage. This is supported by data from a Canadian hospital where downstream testing during the shortage of 99m Tc increased by 77% and radiation exposures to patients doubled. 3 Our study extends this finding to the United States nationally and raises a new concern of decreasing 99m
Tc use overall. Thallium Tl 201 is associated with higher radiation exposure 4 and lower specificity relative to 99m Tc.
Given tension between medical applications of HEU and potential for nuclear weapons proliferation, the US Congress authorized $143 million from 2011 to 2014 to encourage domestic production of 99m Tc from sources other than HEU but has not renewed funding. Export of HEU fuel will be banned starting in 2020, which could severely curtail production of 99m Tc. There was a significant trend toward increased PC use over time (Figure) . Overall, 51.2% (2292 of 4474) of patients with HF died within 1 year of hospitalization. Those who died were more likely to have been seen by PC (10.7% [246 of 2292] vs 4.2% [92 of 2182], P < .001). Those seen by PC had a 1-year mortality of 72.8% (246 of 338) compared with 49.5% (2046 of 4136) among those who were not seen by PC (P < .001). On multivariable analysis, age, year, malignancy, and renal disease were significant predictors of PC use.
Discussion | A strength of our study is an analysis of the largest integrated health care system (the Veteran Affairs Healthcare System) in the United States and an assessment of PC use up to 1 year after HF hospitalization. While use rates doubled during the study period, the absolute rate remained low (7.6% [338 of 4474]). Palliative care use in HF was specific (72.8% [246 of 338 of patients seen by PC died within 1 year) but not very sensitive (10.7% [246 of 2292] of patients who died within 1 year were seen by PC). Absolute rates of PC use in HF were less than the published rate in oncology (17%) 5 and were similar to the published rate in chronic obstructive pulmonary disease (5.1%). 6 This study has several limitations. We analyzed a predominantly male population in an integrated health care system, which may limit generalizability. We lacked data on symptoms or patient preference, which would influence which patients may qualify for PC. Errors in coding are possible, including overcoding or undercoding of PC use in HF. However, interrater reliability assessments are performed quarterly for each abstractor to ensure the accuracy of coding. 4 Our rates of PC use in HF are consistent with prior single-center literature, 1 suggesting external validity.
In conclusion, the use of PC in veterans with severe HF increased over the study duration, with absolute rates similar to chronic obstructive pulmonary disease and lower than cancer. Our data suggest the potential to improve use of PC in severe HF. 
